• Opinion
• [Reporter's View] Improving rare disease care environment
• by Eo, Yun-Ho Jan 17, 2025 05:54am

• Opinion
• [Reporter's View] K-Bio's development and human resource
• by Whang, byung-woo Jan 14, 2025 05:56am

• Opinion
• [Reporter’s View] Korean drugs go international this year
• by Son, Hyung Min Jan 14, 2025 05:56am

• Opinion
• [Reporter's View] Pharma bio stocks shunned for good reason
• by Kim, Jin-Gu Jan 8, 2025 05:53am

• Opinion
• [Reporter's View] Switching of drugs reimbursable
• by Eo, Yun-Ho Jan 6, 2025 05:57am

• Opinion
• [Reporter’s View] The dilemma of companion diagnostics
• by Whang, byung-woo Dec 31, 2024 05:56am

• Opinion
• [Desk’s View] No external reference pricing next year?
• by Lee, Tak-Sun Dec 24, 2024 06:22am

• Opinion
• [Reporter’s View] ERP hits industry again
• by Eo, Yun-Ho Dec 18, 2024 05:55am

• Opinion
• [Reporter's view] The National Assembly must restore
• by Lee, Jeong-Hwan Dec 17, 2024 05:51am

• Opinion
• [Reporter's view] What corporates expect from entering pharm
• by Dec 13, 2024 05:52am